- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Iodinated Contrast Media Alternative: FDA OKs Bayer Importing Foreign-Labeled Iopromide
The Food and Drug Administration (FDA) has given the green light to Bayer to import foreign-labeled iopromide (Ultravist) to help alleviate ongoing supply challenges with iodinated contrast media in the United States.
In light of continued supply issues with iodinated contrast media stemming from a temporary COVID-19-related shutdown of a GE Healthcare manufacturing plant in Shanghai earlier this year, the Food and Drug Adminstration (FDA) is allowing Bayer to import and distribute foreign-labeled iopromide (Ultravist) in the United States.
Bayer emphasized that Ultravist is indicated for intra-arterial and intravenous administration. The modality is contraindicated for intrathecal administration, according to Bayer.
The company added that clinicians should be aware of differences between the package inserts for the foreign-labeled iopromide and the U.S. version, and defer to the U.S. prescribing information for iopromide.
For additional questions about the use of iopromide, one may contact Bayer Healthcare Pharmaceuticals at (888) 842-2937.
(Editor’s note: For related content, see “Iodinated Contrast Media Shortage: Practical Solutions and Applications in Radiology,” “Lessons Learned from the Iodinated Contrast Media Shortage: A Neuroradiologist’s Perspective,” “Emerging Strategies for Managing the Acute Shortage of Iodinated Contrast Media” and “Iodinated Contrast Media: 15 Recommendations for Addressing the Shortage.”)
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
